Jane Street’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31.5M Sell
171,700
-18,200
-10% -$3.35M ﹤0.01% 1399
2025
Q4
$33.4M Sell
189,900
-17,800
-9% -$2.91M 0.01% 1181
2025
Q3
$29.1M Sell
207,700
-115,300
-36% -$15.6M ﹤0.01% 1319
2025
Q2
$40.6M Buy
323,000
+112,700
+54% +$14M 0.01% 903
2025
Q1
$28.8M Buy
210,300
+136,000
+183% +$19.4M 0.01% 1022
2024
Q4
$11.4M Buy
74,300
+9,000
+14% +$1.52M ﹤0.01% 1763
2024
Q3
$12.7M Sell
65,300
-32,000
-33% -$6.69M ﹤0.01% 1673
2024
Q2
$22.6M Buy
97,300
+7,900
+9% +$1.72M 0.01% 1218
2024
Q1
$19.3M Sell
89,400
-7,900
-8% -$1.85M ﹤0.01% 1214
2023
Q4
$25.2M Buy
97,300
+17,600
+22% +$4.32M 0.01% 1083
2023
Q3
$20.5M Buy
79,700
+9,400
+13% +$2.51M 0.01% 1077
2023
Q2
$20M Sell
70,300
-24,900
-26% -$7.41M 0.01% 1207
2023
Q1
$26.5M Sell
95,200
-153,800
-62% -$42.6M 0.01% 830
2022
Q4
$69M Sell
249,000
-314,100
-56% -$88.7M 0.03% 406
2022
Q3
$150M Buy
563,100
+64,500
+13% +$13.7M 0.07% 179
2022
Q2
$102M Buy
498,600
+181,500
+57% +$37.1M 0.04% 310
2022
Q1
$66.8M Sell
317,100
-19,100
-6% -$4.15M 0.02% 550
2021
Q4
$80.7M Buy
336,200
+2,200
+0.7% +$566K 0.03% 449
2021
Q3
$94.5M Sell
334,000
-56,400
-14% -$18.5M 0.03% 357
2021
Q2
$135M Buy
390,400
+165,200
+73% +$50M 0.05% 246
2021
Q1
$63M Sell
225,200
-258,500
-53% -$69.7M 0.03% 416
2020
Q4
$118M Buy
483,700
+159,200
+49% +$41.1M 0.06% 211
2020
Q3
$92.1M Buy
324,500
+62,600
+24% +$17.5M 0.06% 237
2020
Q2
$70.1M Buy
261,900
+95,900
+58% +$28.8M 0.05% 254
2020
Q1
$52.5M Buy
166,000
+36,100
+28% +$11M 0.05% 240
2019
Q4
$38.5M Sell
129,900
-32,800
-20% -$9.1M 0.05% 225
2019
Q3
$37.9M Buy
162,700
+96,200
+145% +$22.4M 0.06% 211
2019
Q2
$15.6M Sell
66,500
-122,900
-65% -$28.4M 0.03% 457
2019
Q1
$44.8M Buy
189,400
+175,600
+1,272% +$55.3M 0.07% 198
2018
Q4
$4.15M Sell
13,800
-6,200
-31% -$1.98M 0.01% 1065
2018
Q3
$7.07M Sell
20,000
-19,600
-49% -$6.75M 0.01% 814
2018
Q2
$11.5M Buy
39,600
+15,500
+64% +$4.36M 0.03% 538
2018
Q1
$6.6M Sell
24,100
-59,500
-71% -$18.5M 0.02% 780
2017
Q4
$26.6M Buy
83,600
+47,800
+134% +$15.3M 0.08% 227
2017
Q3
$11.2M Sell
35,800
-74,700
-68% -$22.1M 0.04% 476
2017
Q2
$30M Buy
110,500
+41,100
+59% +$10.9M 0.11% 169
2017
Q1
$19M Buy
69,400
+35,000
+102% +$9.9M 0.08% 211
2016
Q4
$9.76M Sell
34,400
-8,100
-19% -$2.4M 0.04% 361
2016
Q3
$13.3M Sell
42,500
-50,500
-54% -$15M 0.06% 245
2016
Q2
$22.5M Buy
93,000
+64,200
+223% +$16.9M 0.11% 167
2016
Q1
$7.5M Buy
28,800
+4,600
+19% +$1.22M 0.04% 402
2015
Q4
$7.41M Sell
24,200
-36,300
-60% -$10.4M 0.05% 363
2015
Q3
$17.7M Buy
60,500
+23,100
+62% +$7.63M 0.11% 154
2015
Q2
$15.1M Buy
37,400
+18,200
+95% +$7.3M 0.1% 151
2015
Q1
$8.11M Buy
19,200
+18,600
+3,100% +$7.33M 0.06% 266
2014
Q4
$204K Buy
+600
New +$194K ﹤0.01% 2212

Other funds holding BIIB

Jane Street's BIIB Position: Q1 2026 in Review

Jane Street reduced its Biogen (BIIB) stake by 56% in Q1 2026, selling an estimated $2.41M and leaving 10,469 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #5178.

Jane Street first reported a position in BIIB in Q2 2013 and has held it in 50 quarters since. The position peaked at $81.3M in Q3 2022. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Jane Street held 10,469 shares of Biogen worth $1.92M as of Q1 2026.
  • Jane Street sold 13,070 Biogen shares in Q1 2026, an estimated $2.41M.
  • Biogen made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5178 holding.
  • Jane Street first reported a position in Biogen in Q2 2013 and has held it in 50 quarters since.
  • Jane Street's Biogen position peaked at $81.3M in Q3 2022.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.